Boehringer Ingelheim ( Boehringer-Ingelheim )

Boehringer-Ingelheim

Boehringer Ingelheim's picture

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes.

Boehringer-Ingelheim press release, blog etc

04/25/2018 - 04:32 Boehringer Ingelheim R&D pushes to transcend disease boundaries
04/25/2018 - 03:11 Boehringer Ingelheim has a very successful 2017 financial year
04/11/2018 - 06:38 Boehringer Ingelheim to invest 65 million in avian vaccines
04/04/2018 - 12:34 Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
03/28/2018 - 02:55 Boehringer Ingelheim announces the 2018 BVDzero Case Awards
03/26/2018 - 03:47 Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
03/19/2018 - 08:31 FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
03/13/2018 - 08:05 Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
02/21/2018 - 01:54 Boehringer Ingelheim: 2018 European PRRS Research Award open for submissions until
02/16/2018 - 06:02 Systemic Sclerosis World Congress: Inspirational patient stories reveal the challenging realities of living with devastating rare disease
02/09/2018 - 06:26 Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimers trials
01/15/2018 - 03:20 The World Association for Buiatrics and Boehringer Ingelheim announce the 2018 'Ruminant Well-Being Awards
01/09/2018 - 00:31 BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
01/03/2018 - 05:01 Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M
12/19/2017 - 03:55 Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
12/18/2017 - 05:34 Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
12/15/2017 - 05:26 Change in the Board of Managing Directors at Boehringer Ingelheim
12/11/2017 - 09:48 Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017